|Day's Range||0.90 - 1.00|
|52 Week Range||0.26 - 1.51|
|PE Ratio (TTM)||-3.21|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Protalix medicine alidornase alfa is designed to help cystic fibrosis patients clear their lungs by making mucus thin and loose.
Options traders are pricing in a big move for Protalix BioTherapeutics (PLX) shares as it has huge implied volatility
Categories: Yahoo Finance Get free summary analysis Protalix Biotherapeutics, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Protalix Biotherapeutics, Inc. – Amicus Therapeutics, Inc., Pfizer Inc., Neurocrine Biosciences, Inc., Aviragen Therapeutics Inc and Teva Pharmaceutical Industries Limited Sponsored ADR (FOLD-US, PFE-US, NBIX-US, AVIR-US and TEVA-US) ... Read more (Read more...)